Uses of Autologous Serum in Ocular Surface Diseases: A 10-Year Experience and Review of the Literature.

IF 1.9 4区医学 Q2 OPHTHALMOLOGY

Seminars in Ophthalmology Pub Date : 2025-07-07 DOI:10.1080/08820538.2025.2528213

Alfredo Domínguez-López, Beatriz Buentello-Volante, Norma Magaña-Guerrero, Fátima Sofía Magaña-Guerrero, Óscar Vivanco-Rojas, Enrique O Graue Hernández, Yonathan Garfias

{"title":"Uses of Autologous Serum in Ocular Surface Diseases: A 10-Year Experience and Review of the Literature.","authors":"Alfredo Domínguez-López, Beatriz Buentello-Volante, Norma Magaña-Guerrero, Fátima Sofía Magaña-Guerrero, Óscar Vivanco-Rojas, Enrique O Graue Hernández, Yonathan Garfias","doi":"10.1080/08820538.2025.2528213","DOIUrl":null,"url":null,"abstract":"Purpose: The aim of this study was to identify the diagnoses that led to the prescription of autologous serum (AS) in a tertiary eye care center over a 10-year period and to contextualize these findings through a comprehensive review of the literature.Methods: A retrospective case series was conducted including records of patients who were prescribed AS for the first time between January 2015 and December 2024. In parallel, we analyzed more than 30 clinical studies, including randomized controlled trials and observational reports, investigating the efficacy, safety, and concentration strategies of AS in various ocular surface diseases.Results: A total of 1,108 patients were included (mean age: 60.6±15.9 years; 81% female), with most patients between 50 and 79 years old. The most frequent diagnoses included non-Sjögren dry eye (36.4%), and primary (16.3%) and secondary (6.6%) Sjögrenös syndrome-related dry eye, with 20% and 30% being the most commonly prescribed concentrations. The literature supports the use of AS, particularly at a concentration of 20%, in conditions such as dry eye and Sjögren's syndrome, which is consistent with our findings.Conclusions: This integrated analysis provides valuable insight into current clinical practice and may support future decision-making in the treatment of ocular surface disease.","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"1-8"},"PeriodicalIF":1.9000,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08820538.2025.2528213","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: The aim of this study was to identify the diagnoses that led to the prescription of autologous serum (AS) in a tertiary eye care center over a 10-year period and to contextualize these findings through a comprehensive review of the literature.

Methods: A retrospective case series was conducted including records of patients who were prescribed AS for the first time between January 2015 and December 2024. In parallel, we analyzed more than 30 clinical studies, including randomized controlled trials and observational reports, investigating the efficacy, safety, and concentration strategies of AS in various ocular surface diseases.

Results: A total of 1,108 patients were included (mean age: 60.6±15.9 years; 81% female), with most patients between 50 and 79 years old. The most frequent diagnoses included non-Sjögren dry eye (36.4%), and primary (16.3%) and secondary (6.6%) Sjögrenös syndrome-related dry eye, with 20% and 30% being the most commonly prescribed concentrations. The literature supports the use of AS, particularly at a concentration of 20%, in conditions such as dry eye and Sjögren's syndrome, which is consistent with our findings.

Conclusions: This integrated analysis provides valuable insight into current clinical practice and may support future decision-making in the treatment of ocular surface disease.

查看原文本刊更多论文

自体血清在眼表疾病中的应用：10年的经验和文献综述。

目的：本研究的目的是确定三级眼科护理中心10年来导致自体血清（AS）处方的诊断，并通过对文献的全面回顾将这些发现联系起来。方法：回顾性分析2015年1月至2024年12月首次使用AS的患者。同时，我们分析了30多项临床研究，包括随机对照试验和观察性报告，调查了AS在各种眼表疾病中的疗效、安全性和浓度策略。结果：共纳入1108例患者(平均年龄：60.6±15.9岁；81%为女性)，大多数患者年龄在50至79岁之间。最常见的诊断包括non-Sjögren干眼症（36.4%）、原发性（16.3%）和继发性（6.6%）Sjögrenös综合征相关干眼症，其中20%和30%是最常见的处方浓度。文献支持在干眼和Sjögren综合征等情况下使用AS，特别是在浓度为20%时，这与我们的发现是一致的。结论：这一综合分析为当前的临床实践提供了有价值的见解，并可能支持未来治疗眼表疾病的决策。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Seminars in Ophthalmology OPHTHALMOLOGY-

CiteScore

3.20

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Seminars in Ophthalmology offers current, clinically oriented reviews on the diagnosis and treatment of ophthalmic disorders. Each issue focuses on a single topic, with a primary emphasis on appropriate surgical techniques.